ERBB2 and breast carcinoma: As a result of Destiny Breast-04, T-DXd is approved for patients with unresectable or metastatic HER2-low breast cancer who have received one prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.